Published in Minerva Anestesiol on September 01, 1991
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia (2009) 1.80
A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol (1998) 1.55
Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. Haematologica (1998) 1.49
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res (2010) 1.40
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. Haematologica (1999) 1.39
Splenic injury: management in the Languedoc-Roussillon region. J Visc Surg (2010) 1.39
Increased CD10/TdT positive cells in the bone marrow of an infant with immune thrombocytopenia. Haematologica (1994) 1.38
Clinical and electrophysiologic evolution of the Wolff-Parkinson-White syndrome in children: impact on approaches to management. Cardiol Young (2000) 1.36
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol (2008) 1.34
Respiratory mechanics in anesthetized paralyzed humans: effects of flow, volume, and time. J Appl Physiol (1985) (1989) 1.18
Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol (2004) 1.14
Pulmonary and chest wall mechanics in anesthetized paralyzed humans. J Appl Physiol (1985) (1991) 1.09
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol (2001) 1.08
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol (2011) 1.07
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol (2013) 1.05
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol (2011) 1.02
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol (2009) 1.01
Comparison of nutritional status after total or subtotal gastrectomy. Nutrition (1992) 1.00
Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood (2001) 0.99
Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol (2000) 0.97
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. Leukemia (2011) 0.97
Human umbilical cord blood: immunophenotypic heterogeneity of CD34+ hematopoietic progenitor cells. Haematologica (1997) 0.94
Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol (1999) 0.92
Cascade of bulk magnetic phase transitions in NaxCoO2 as studied by muon spin rotation. Phys Rev Lett (2005) 0.91
CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma (2001) 0.91
Spontaneous remission in acute myeloid leukaemia: a role for endogenous production of tumour necrosis factor and interleukin-2? Br J Haematol (1994) 0.90
Blood cell flow cytometry in paroxysmal nocturnal hemoglobinuria: a tool for measuring the extent of the PNH clone. Leukemia (1996) 0.89
CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype. Haematologica (1998) 0.88
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia (2012) 0.88
Serum levels of cytokines and soluble antigens in polytransfused patients with beta-thalassemia major: relationship to immune status. Haematologica (1995) 0.87
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia (2011) 0.86
Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood (1998) 0.86
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol (2012) 0.85
Anorexia in cancer patients: prevalence and impact on the nutritional status. Clin Nutr (1989) 0.85
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol (2014) 0.85
Effect of PEEP on respiratory mechanics in anesthetized paralyzed humans. J Appl Physiol (1985) (1992) 0.85
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2)). Leukemia (2004) 0.84
Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? Blood (1996) 0.84
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene (2011) 0.84
Vaccination against influenza in multiple myeloma. Br J Haematol (1997) 0.83
Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica (1996) 0.83
Prognosis of chronic myelomonocytic leukemia. Haematologica (1996) 0.83
Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density. Leuk Lymphoma (2001) 0.83
Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure. Nephrol Dial Transplant (1999) 0.82
Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion (2001) 0.82
Neutron spin-echo investigation of slow spin dynamics in kagomé-bilayer frustrated magnets as evidence for phonon assisted relaxation in SrCr9xGa12-9xO19. Phys Rev Lett (2006) 0.82
Identification of three novel mutations in the PIG-A gene in paroxysmal nocturnal haemoglobinuria (PNH) patients. Hum Genet (1996) 0.82
Targeting regulatory T cells for anticancer therapy. Mini Rev Med Chem (2011) 0.81
[Loco-regional block in ophthalmic surgery: single drug or drug combination with hyaluronidase? Randomized prospective study]. Minerva Anestesiol (1999) 0.81
Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia (1996) 0.81
CD69 expression in B-cell chronic lymphocytic leukemia: a new prognostic marker ? Haematologica (2001) 0.81
Ground state of the kagomé-like S=1/2 antiferromagnet volborthite Cu3V2O7(OH)2 x 2H2O. Phys Rev Lett (2005) 0.81
Oncocytic nonsecretory multiple myeloma. A clinicopathologic study of a case and review of the literature. Acta Haematol (1996) 0.80
Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis. Haematologica (1997) 0.79
Electrophoretic karyotype of Mucor circinelloides. Curr Genet (1994) 0.79
Thy-1 (CDw90) and c-kit receptor (CD117) expression on CD34+ hematopoietic progenitor cells: a five dimensional flow cytometric study. Haematologica (1998) 0.79
Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report. Bone Marrow Transplant (1996) 0.79
Q fever epidemic in Hungary, April to July 2013. Euro Surveill (2014) 0.79
Electrical and mechanical output of the expiratory muscles in anesthetized dogs. Respir Physiol (1991) 0.79
Superconductivity in a molecular metal cluster compound. Phys Rev Lett (2006) 0.78
Hospital malnutrition: incidence and prospective evaluation of general medical patients during hospitalization. Acta Vitaminol Enzymol (1984) 0.78
Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia. Int J Immunopathol Pharmacol (2013) 0.78
CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica (2000) 0.78
Symptomatic myopathy during interferon alfa therapy for chronic myelogenous leukemia. Leukemia (1998) 0.78
Insights into defibrotide: an updated review. Expert Opin Biol Ther (2009) 0.78
[An unusual case of postoperative mechanical obstruction of the upper respiratory tract in a child]. Minerva Anestesiol (1977) 0.77
Effects of sympathetic blockade on the efficiency of forced-air warming during combined spinal-epidural anesthesia for total hip arthroplasty. J Clin Anesth (1999) 0.77
A phase II trial on alpha-interferon (alpha IFN) effect in patients with monoclonal IgM gammopathy. Leuk Lymphoma (1994) 0.77
A prospective study comparing rapid assessment of smears and ThinPrep for endoscopic ultrasound-guided fine-needle aspirates. Endoscopy (2010) 0.77
Metalloendopeptidase QG. Isolation from Escherichia coli and characterization. Biochem J (1991) 0.77
CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica (1998) 0.77
Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma. Br J Haematol (1995) 0.77
Serum beta 2-microglobulin in malignant lymphoproliferative disorders. Tumori (1988) 0.77
Myelomatous nodular lesions of the liver: diagnosis by ultrasound-guided fine-needle biopsy. J Clin Ultrasound (1993) 0.77
Effect of cyclosporin-A on anemia in idiopathic myelofibrosis. Haematologica (1998) 0.76
Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases. Haematologica (1996) 0.76
Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone. Support Care Cancer (2012) 0.76
Shortening the discharging time after total hip replacement under combined spinal/epidural anesthesia by actively warming the patient during surgery. Minerva Anestesiol (1999) 0.76
Conventional induction treatments do not influence overall survival in multiple myeloma. Br J Haematol (1997) 0.76
Soluble transferrin receptor in beta-thalassaemia. Lancet (1993) 0.76
Tumor necrosis factor-alpha and interleukin-1 beta. Two possible mediators of allergic inflammation. Minerva Pediatr (1996) 0.75
Soluble intercellular adhesion molecule-1 correlates with markers of disease activity in B-cell chronic lymphocytic leukemia. Blood (1995) 0.75
Again about bone marrow necrosis: particular diagnostic aspects. Hematol Pathol (1989) 0.75
Plasma cell acid phosphatase in multiple myeloma. Blood (1993) 0.75
Recombinant erythropoietin for myelodysplastic syndromes. Br J Haematol (1995) 0.75
All-trans retinoic acid for advanced multiple myeloma. Blood (1995) 0.75
Treatment of plasma cell leukaemia and resistant/relapsed multiple myeloma with vincristine, mitoxantrone and dexamethasone (VMD protocol) Br J Haematol (1991) 0.75
CFU-GM are not increased in peripheral blood of patients with chronic lymphocytic leukaemia. Eur J Haematol (1996) 0.75
Circulating CD34+ absolute cell number is the best single parameter to predict the quality of leukapheretic yield. Bone Marrow Transplant (1998) 0.75
Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone? Blood (1994) 0.75
[Antiarrhythmic action of modern local anesthetics. II. Action on experimental arrhythmias induced with adrenaline]. Minerva Anestesiol (1969) 0.75
[Theoretical aspects of renal elimination via non-ionic diffusion of acids and weak bases]. Minerva Anestesiol (1968) 0.75
[Cardiac toxicity of modern local anesthetics. Electrocardiographic study]. Minerva Anestesiol (1969) 0.75
[Antiarrhythmic activity of a new local anesthetic (F.I. 6655)]. Minerva Anestesiol (1969) 0.75
[Antiarrhythmic action of modern local anesthetics. I. Action on experimental arrhythmias induced with ouabain]. Minerva Anestesiol (1969) 0.75
[Striated muscle fibers and CI-581]. Minerva Anestesiol (1969) 0.75
[Neuroleptic malignant syndrome. Problems of differential diagnosis. Description of a clinical case]. Minerva Anestesiol (1992) 0.75
[Cardiac toxicity of a new local anesthetic (F.I. 6655). Electrocardiographic study]. Minerva Anestesiol (1969) 0.75
[Considerations on the theoretical and practical possibilities of modifying the pharmacodynamics of various drugs]. Minerva Anestesiol (1968) 0.75